Is Ipamorelin legal: Frequently asked questions

A CoA is necessary but not sufficient for compliance. The CoA must show third-party verification (HPLC for purity, mass spectrometry for identity, endotoxin testing for sterility) and be tied to the specific batch you're receiving. Many unregistered suppliers provide generic CoAs or outdated test results that don't correspond to the shipped product. Legal compliance requires the supplier to be FDA-registered or state-licensed, provide batch-specific documentation, and avoid therapeutic marketing claims. If the CoA lacks third-party verification or the supplier's website includes performance-enhancing language, the purchase is legally questionable regardless of the CoA's presence.

Clinical trials involving ipamorelin require an active Investigational New Drug (IND) application submitted to and approved by the FDA before any human dosing begins. The IND process includes preclinical safety data, chemistry and manufacturing controls documentation, clinical protocol design, and investigator qualifications. Purchasing ipamorelin for clinical use without an approved IND is a federal violation. Even Phase 0 microdosing trials or exploratory studies require IND coverage. There are no informal pathways for human administration of unapproved compounds.

That constitutes illegal use of an unapproved drug. Ipamorelin purchased under research exemptions is legally restricted to the documented research protocol. Diverting research-grade peptides to personal use. Even if you're the principal investigator on the research project. Violates federal drug law and institutional research integrity policies. Institutional audits and regulatory inspections track peptide inventory against documented use; discrepancies trigger compliance investigations that can result in loss of research privileges, institutional sanctions, and federal enforcement referrals.

No, not as an individual. The purchase must go through your institution's procurement system with faculty advisor approval and IRB oversight. Graduate students conducting peptide research order compounds through departmental accounts tied to approved research protocols. Direct individual purchases from suppliers are flagged as non-compliant. Your institution's research compliance office and your faculty advisor must authorize the purchase, verify the supplier's registration status, and document the peptide's role in your approved research plan.

Do not prescribe ipamorelin for human use outside of an FDA-approved IND protocol. Doing so constitutes off-label use of an unapproved drug and exposes the prescriber to federal enforcement, state medical board disciplinary action, and civil liability. The FDA's removal of ipamorelin from the 503B bulk substances list in 2023 means compounding pharmacies cannot legally prepare it for human administration, even with a prescription. Physicians seeking to use growth hormone secretagogues for therapeutic purposes should consider FDA-approved alternatives such as tesamorelin (Egrifta) for HIV-associated lipodystrophy or evaluate whether the patient qualifies for enrollment in an active clinical trial investigating ipamorelin under an IND application.

Avoid purchasing from that supplier. The absence of proper labeling signals either non-compliance with federal requirements or intentional positioning for non-research buyers, both of which introduce legal risk for downstream purchasers. Research institutions and laboratories that source peptides from non-compliant vendors can face secondary liability if the supplier is later subject to FDA enforcement actions, particularly if the institution's purchasing records suggest knowledge of improper marketing. Due diligence requires verifying that every peptide order includes explicit research-use-only designations on both outer packaging and product vials, and that the supplier maintains documented quality control processes including third-party analytical testing.

Cease use immediately and notify the supplier to request a replacement or refund. Contaminated or low-purity peptides introduce uncontrolled variables that compromise experimental validity. Document the failed purity result with photographic evidence of the CoA and any internal testing data, then escalate the issue to the institutional procurement office if the supplier does not respond. If the peptide was used in any experiments prior to discovering the purity issue, those data points should be flagged in lab notebooks and excluded from publication unless the specific contaminants can be identified and shown not to interfere with the experimental endpoint. Some institutional biosafety committees require formal incident reporting when research reagents fail quality specifications, particularly if the compound was used in animal models.

Source the peptide only from suppliers who provide batch-specific certificates of analysis and research-use-only labeling. If a purchase was completed without these documents, contact the supplier immediately to obtain retroactive documentation. If they cannot provide it, the peptide should not be used in any protocol that requires regulatory compliance or publication. Institutional review boards and journal editors increasingly require proof of reagent purity and proper sourcing as part of reproducibility standards, and the absence of this documentation can invalidate study results or trigger retractions. Laboratories operating under NIH or NSF grants face additional scrutiny: federal audit guidelines require that all research materials be sourced from vendors who meet documented quality standards.